RPE65 and Leber congenital amaurosis 2: The Food and Drug Administration (FDA) approval of Luxturna (voretigene neparvovec-rzyl) in 2017 marked a significant milestone, providing a functional copy of the Retinal Pigment Epithelium-specific 65 kDa protein (RPE65) gene to patients with Leber congenital amaurosis type 2 (LCA-2) [5].